Medical Therapy. Adverse Effects or Lack of Adverse Effects

Treprostinil Is Associated With Early and Sustained Improvement in Group 3 Pulmonary Hypertension and Right Ventricular Function in Children

Kaushik Parvathaneni, Justin J. Kochanski, Megha D. Tandel, Esther Liu, Alisa Arunamata, Jeffrey A. Feinstein, Rachel K. HopperStanford University School of Medicine and Stanford University.United States Pulmonary CirculationPulm Circ 2026; 16: DOI: 10.1002/pul2.70304 AbstractUse of subcutaneous treprostinil (TRE) in children with pulmonary hypertension (PH) secondary to lung disease (group 3 PH) is not well described. We […]

Treprostinil Is Associated With Early and Sustained Improvement in Group 3 Pulmonary Hypertension and Right Ventricular Function in Children Read More »

Early Results of Sotatercept Treatment in Patients With Severe Pulmonary Hypertension and a Potts Shunt

Manish A. Aggarwal, Kelly Merrill, Delphine Yung, R. Mark GradyWashington University and St Louis Children’s Hospital. University of Washington and Seattle Children’s Hospital.United States Pulmonary CirculationPulm Circ 2026; 16: DOI: 10.1002/pul2.70296 AbstractTwelve patients with severe pulmonary hypertension (PH) who had a pulmonary artery-to-descending aorta (Potts) shunt were treated with the novel PH drug sotatercept for an

Early Results of Sotatercept Treatment in Patients With Severe Pulmonary Hypertension and a Potts Shunt Read More »

Sildenafil for bronchopulmonary dysplasia-associated pulmonary hypertension: A systematic search and narrative synthesis

Yoshinori Katayama, Katsuya Hirata, Yutaka Nishimura, Atsuko, Nakahari, Mami Takeoka, Masahiko Watanabe, Tetsuya Isayama, Japan Evidence Based NeonatologyTakatsuki General Hospital. Osaka Women’s and Children’s Hospital. Hiroshima City Hiroshima Citizens Hospital. Jichi Medical University Saitama Medical Center. Mie University Graduate School of Medicine. National Center for Child Health and Development.Japan Pediatrics InternationalPediatr Int 2026; 68: DOI: 10.1111/ped.70385

Sildenafil for bronchopulmonary dysplasia-associated pulmonary hypertension: A systematic search and narrative synthesis Read More »

Postnatal Steroids in Preterm Infants: A Narrative Review Series-Part 2: Cardiovascular Impacts

Phoenix Plessas-Azurduy, Anie Lapointe, Punnanee Wutthigate, Sarah Spénard, Andréanne Villeneuve, Audrey Hébert, Eilon Shany, Justin Richardson, Neta Geva, Wadi Mawad, Tiscar Cavallé-Garrido, Marc Beltempo, Wissam Shalish, Guilherme Sant’Anna, Gabriel AltMcGill University. Université de Montréal, CHU Sainte-Justine. Mahidol University. Montreal Children’s Hospital. CHU de Québec and Laval University. Saban Children’s Hospital and Soroka Medical Center. Ben

Postnatal Steroids in Preterm Infants: A Narrative Review Series-Part 2: Cardiovascular Impacts Read More »

Protocol for an open-label, randomised, controlled trial to evaluate the efficacy and safety of sotatercept add-on therapy compared with pulmonary vasodilator-based standard of care for pulmonary vasodilator-resistant pulmonary arterial hypertension associated with unrepaired congenital shunts (atrial septal defect, ventricular septal defect or patent ductus arteriosus), including Eisenmenger syndrome: the SuMILE trial

Keimei Yoshida, Kazuya Hosokawa, Takahiro Hiraide, Satoshi Akagi, Kentaro Ejiri, Yu Taniguchi, Shiro Adachi, Takumi Inami, Naohiko Nakanishi, Masaharu Kataoka, Taijyu Satoh, Shunsuke Tatebe, Toshiro Shinke, Hideshi Tomita, Yusuke Akazawa, Takashi Higaki, Koshiro Tagawa, Ayako Ishikita, Soshun Asakawa, Kohtaro AbeKyushu University and Kyushu University Hospital. Keio University School of Medicine. Okayama University. Kobe University Hospital.

Protocol for an open-label, randomised, controlled trial to evaluate the efficacy and safety of sotatercept add-on therapy compared with pulmonary vasodilator-based standard of care for pulmonary vasodilator-resistant pulmonary arterial hypertension associated with unrepaired congenital shunts (atrial septal defect, ventricular septal defect or patent ductus arteriosus), including Eisenmenger syndrome: the SuMILE trial Read More »

Sotatercept in Patients With Eisenmenger Syndrome

Oktay Tutarel, Oliver Miera, Felix BergerDeutsches Herzzentrum der Charité, Freie Universität Berlin and Humboldt-Universität zu Berlin.Germany Pulmonary CirculationPulm Circ 2026; 16: DOI: 10.1002/pul2.70283 AbstractEisenmenger syndrome represents a complex and severe form of pulmonary arterial hypertension (PAH) associated with congenital heart disease. Sotatercept, a first-in-class activin-signaling inhibitor, offers a novel therapeutic approach in the treatment of PAH,

Sotatercept in Patients With Eisenmenger Syndrome Read More »

Macitentan vs Standard of Care in Pediatric Pulmonary Arterial Hypertension (TOMORROW): A Randomized Clinical Trial

Rolf M. F. Berger, D. Dunbar Ivy, Julian I. Borissoff, Sofija Cerovic, Dénes Csonka, Tatiana Remenová, Dominik Richard, Matthieu Villeneuve, Maurice BeghettiBeatrix Children’s Hospital, University Medical Center Groningen and University of Groningen. Children’s Hospital Colorado. Johnson & Johnson. University Hospitals of Geneva.Netherlands, United States and Switzerland Journal of PediatricsJ Pediatr 2026; DOI: 10.1016/j.jpeds.2026.115057 AbstractObjectives: To evaluate pharmacokinetics

Macitentan vs Standard of Care in Pediatric Pulmonary Arterial Hypertension (TOMORROW): A Randomized Clinical Trial Read More »

Pathophysiology and prevalence of high output heart failure in group 1 pulmonary hypertension

Yogesh N V Reddy 1, Robert P Frantz 2, William R Miranda 2, Revati Varma 2, Paul M Hassoun 3, Anna R Hemnes 4, Evelyn Horn 5, Jane A Leopold 6, Franz Rischard 7, Erika B Rosenzweig 8, Nicholas S Hill 9, Serpil C Erzurum 10, Gerald J Beck 11, Samar Farha 12, J Emanuel Finet 12, Christine Jellis 12, Deborah Kwon 12, Stephen Mathai 3, Margaret Park 12, W H Wilson Tang 12, Barry A Borlaug 2; PVDOMICS Study GroupMayo Clinic. Johns Hopkins University. Vanderbilt University Medical Center. Weill Cornell Medicine. Brigham and Women’s Hospital and

Pathophysiology and prevalence of high output heart failure in group 1 pulmonary hypertension Read More »

Systematic Review of the Application of Pulmonary Hypertension Treatments in Ventricular Septal Defect, Pulmonary Atresia, and Major Aortopulmonary Collateral Arteries

Keiichi Hirono, Keiko Uchida, Taku Ishii, Hidekazu Ishida, Shinichi Takatsuki, Hiroyuki Fukushima, Kei Inai, Susumu Hosokawa, Reina Ishizaki, Hirofumi Sawada, Naofumi F. Sumitomo, Ayako Chida-Nagai, Yuichi Ishikawa, Hirohiko Motoki, Atsushi Yao, Shigetoyo Kogaki, Hiroyuki Yamagishi, Shozaburo DoiToyama University Hospital. Tokyo Medical University. Institute of Science Tokyo. Osaka University Graduate School of Medicine. Toho University, Omori

Systematic Review of the Application of Pulmonary Hypertension Treatments in Ventricular Septal Defect, Pulmonary Atresia, and Major Aortopulmonary Collateral Arteries Read More »

Safety of a novel portable inhaled nitric oxide generator for therapy of persistent pulmonary hypertension in neonates: a case series study

Yao Zhu, Jiongzhi He, Miner Cai, Lijun Wen, Minxu LiDongguan Maternal and Child Health Care Hospital. First Affiliated Hospital of Jinan University.China Translational PediatricsTransl Pediatr 2025; 14: 3305-3317DOI: 10.21037/tp-2025-535 AbstractBackground: Persistent pulmonary hypertension of the newborn (PPHN) is a life-threatening emergency in neonatal intensive care. Traditional treatments such as cylinder-based nitric oxide (NO) delivery systems rely on

Safety of a novel portable inhaled nitric oxide generator for therapy of persistent pulmonary hypertension in neonates: a case series study Read More »

Scroll to Top